MGP was verified as a reliable marker with extremely high sensitivity in all subtypes of breast carcinoma (87.3–91.2%), which is comparable to TRPS1 and much higher than GATA3 in HER2+ and TNBC subtypes. Here, ERBB2 is linked to breast carcinoma.